A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BeOne Medicines
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
IDEAYA Biosciences
Revolution Medicines, Inc.
University Hospital Heidelberg
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
Eli Lilly and Company
Pfizer
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Amgen
Replimune Inc.
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Roswell Park Cancer Institute
Seagen Inc.
AgonOx, Inc.
Novartis
TILT Biotherapeutics Ltd.
University Health Network, Toronto
Integro Theranostics
National Cancer Institute (NCI)
AstraZeneca
Massachusetts General Hospital
M.D. Anderson Cancer Center
University of California, Irvine
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
HUYABIO International, LLC.
City of Hope Medical Center
BeiGene
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Compugen Ltd
National Cancer Institute (NCI)
Checkpoint Therapeutics, Inc.
Jonsson Comprehensive Cancer Center